Mergers & Acquisitions - Financial, Immunologicals

Filter

Current filters:

FinancialImmunologicals

Popular Filters

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

Parexel

Parexel

Back to top